Compare BridgeBio Pharma Inc (BBIO) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs KeyCorp — how do they compare? BridgeBio Pharma Inc trades at $84.87 (market cap $16.46B), while KeyCorp trades at $23.33 (market cap $25.15B). The key difference: KeyCorp is the larger of the two by market cap, and KeyCorp pays a 3.52% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | KEY | |
|---|---|---|
Market Cap | $16.46B | $25.15B |
Sector | Health | Financials |
52-Week High | $90.17 | $23.43 |
52-Week Low | $44.81 | $16.78 |
Enterprise Value | $18.02B | — |
Dividend Yield | — | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
KeyCorp (KEY) trades at $23.22, down 0.34% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamental recovery with Q1 2026 EPS beating expectations at $0.44 and a net income margin of 26.05% for 2025. Analyst consensus is heavily bullish with a $29.32 price target, and recent news highlights partnerships and a new $3 billion buyback program.
The outlook for KEY is positive, driven by earnings beats, robust capital returns, and improving profitability. Risks include volatile cash flows and macroeconomic sensitivity, but institutional support and a low P/E of 14.25 suggest undervaluation, offering potential upside for investors seeking regional bank exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
